|
1
|
Khalil DN, Smith EL, Brentjens RJ and
Wolchok JD: The future of cancer treatment: Immunomodulation, CARs
and combination immunotherapy. Nat Rev Clin Oncol. 13:3942016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sharma P, Wagner K, Wolchok JD and Allison
JP: Novel cancer immunotherapy agents with survival benefit: Recent
successes and next steps. Nat Rev Cancer. 11:805–812. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saâda-Bouzid E, Defaucheux C, Karabajakian
A, Coloma VP, Servois V, Paoletti X, Even C, Fayette J, Guigay J,
Loirat D, et al: Hyperprogression during anti-PD-1/PD-L1 therapy in
patients with recurrent and/or metastatic head and neck squamous
cell carcinoma. Ann Oncol. 28:1605–1611. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li X, Zheng L, Zhang F, Hu J, Chou J, Liu
Y, Xing Y and Xi T: STARD13-correlated ceRNA network inhibits EMT
and metastasis of breast cancer. Oncotarget. 7:23197–23211.
2016.PubMed/NCBI
|
|
6
|
Miao L, Liu K, Xie M, Xing Y and Xi T:
miR-375 inhibits Helicobacter pylori-induced gastric carcinogenesis
by blocking JAK2-STAT3 signaling. Cancer Immunology Immunother.
63:699–711. 2014. View Article : Google Scholar
|
|
7
|
Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI,
Park YM, Oh S, Shin JG, Yao S, Chen L and Choi IH: Interferon
regulatory factor-1 is prerequisite to the constitutive expression
and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett.
580:755–762. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bellucci R, Martin A, Bommarito D, Wang K,
Hansen SH, Freeman GJ and Ritz J: Interferon-γ-induced activation
of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells
through upregulation of PD-L1 expression. Oncoimmunology.
4:e10088242015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Coombs MR, Harrison ME and Hoskin DW:
Apigenin inhibits the inducible expression of programmed death
ligand 1 by human and mouse mammary carcinoma cells. Cancer Lett.
380:424–433. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cui F, Wang S, Lao I, Zhou C, Kong H,
Bayaxi N, Li J, Chen Q, Zhu T and Zhu H: miR-375 inhibits the
invasion and metastasis of colorectal cancer via targeting SP1 and
regulating EMT-associated genes. Oncol Rep. 36:487–93. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yi J, Jin L, Chen J, Feng B, He Z, Chen L
and Song H: MiR-375 suppresses invasion and metastasis by direct
targeting of SHOX2 in esophageal squamous cell carcinoma. Acta
Biochim Biophys Sin. 49:159–169. 2017.PubMed/NCBI
|
|
12
|
Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y,
Yao H, Liu X, Ke Y, Si J and Zhou T: MiR-375 frequently
downregulated in gastric cancer inhibits cell proliferation by
targeting JAK2. Cell Res. 20:784–793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sheng B, Zhao L, Zang X, Zhen J and Chen
W: miR-375 ameliorates sepsis by downregulating miR-21 level via
inhibiting JAK2-STAT3 signaling. Biomed Pharmacother. 86:254–261.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harris T, Jimenez L, Kawachi N, Fan JB,
Chen J, Belbin T, Ramnauth A, Loudig O, Keller CE, Smith R, et al:
Low-level expression of miR-375 correlates with poor outcome and
metastasis while altering the invasive properties of head and neck
squamous cell carcinomas. Am J Pathol. 180:917–928. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nohata N, Hanazawa T, Kikkawa N, Mutallip
M, Sakurai D, Fujimura L, Kawakami K, Chiyomaru T, Yoshino H,
Enokida H, et al: Tumor suppressive microRNA-375 regulates oncogene
AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). J Hum
Genet. 56:595–601. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jimenez L, Sharma VP, Condeelis J, Harris
T, Ow TJ, Prystowsky MB, Childs G and Segall JE: MicroRNA-375
suppresses extracellular matrix degradation and invadopodial
activity in head and neck squamous cell carcinoma. Arch Pathol Lab
Med. 139:1349–1361. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ock CY, Kim S, Keam B, Kim M, Kim TM, Kim
JH, Jeon YK, Lee JS, Kwon SK, Hah JH, et al: PD-L1 expression is
associated with epithelial-mesenchymal transition in head and neck
squamous cell carcinoma. Oncotarget. 7:15901–15914. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu X, Wen Z, Xu LZ and Darnell JE Jr:
Stat1 serine phosphorylation occurs independently of tyrosine
phosphorylation and requires an activated Jak2 kinase. Mol Cell
Biol. 17:6618–6623. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mann JE, Hoesli R, Michmerhuizen NL,
Devenport SN, Ludwig ML, Vandenberg TR, Matovina C, Jawad N,
Mierzwa M, Shuman AG, et al: Surveilling the potential for
precision medicine-driven PD-1/PD-L1-targeted therapy in HNSCC. J
Cancer. 8:332–344. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang W, Chen PW, Li H, Alizadeh H and
Niederkorn JY: PD-L1: PD-1 interaction contributes to the
functional suppression of T-cell responses to human uveal melanoma
cells in vitro. Invest Ophthalmol Vis Sci. 49:2518–2525. 2008.
View Article : Google Scholar : PubMed/NCBI
|
